ZA200607291B - Chemically stable compositions of 4-hydroxy tamoxifen - Google Patents

Chemically stable compositions of 4-hydroxy tamoxifen

Info

Publication number
ZA200607291B
ZA200607291B ZA2006/07291A ZA200607291A ZA200607291B ZA 200607291 B ZA200607291 B ZA 200607291B ZA 2006/07291 A ZA2006/07291 A ZA 2006/07291A ZA 200607291 A ZA200607291 A ZA 200607291A ZA 200607291 B ZA200607291 B ZA 200607291B
Authority
ZA
South Africa
Prior art keywords
chemically stable
stable compositions
hydroxy tamoxifen
tamoxifen
hydroxy
Prior art date
Application number
ZA2006/07291A
Other languages
English (en)
Inventor
Dana Hilt
Valerie Masini-Eteve
Richard Fedynec
Brigitte Taravella
Original Assignee
Besins Healthcare Luxemboung Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins Healthcare Luxemboung Sarl filed Critical Besins Healthcare Luxemboung Sarl
Publication of ZA200607291B publication Critical patent/ZA200607291B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA2006/07291A 2004-03-22 2006-08-31 Chemically stable compositions of 4-hydroxy tamoxifen ZA200607291B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/805,530 US20050208139A1 (en) 2004-03-22 2004-03-22 Chemically stable compositions of 4-hydroxy tamoxifen
EP04290762A EP1579857A1 (en) 2004-03-22 2004-03-22 Chemically stable compositions of 4-hydroxy tamoxifen
PCT/EP2005/003455 WO2005092310A2 (en) 2004-03-22 2005-03-18 Chemically stable compositions of 4-hydroxy tamoxifen

Publications (1)

Publication Number Publication Date
ZA200607291B true ZA200607291B (en) 2008-04-30

Family

ID=34854723

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2006/07291A ZA200607291B (en) 2004-03-22 2006-08-31 Chemically stable compositions of 4-hydroxy tamoxifen

Country Status (21)

Country Link
US (1) US20050208139A1 (enExample)
EP (4) EP1579857A1 (enExample)
JP (1) JP5489407B2 (enExample)
CN (1) CN101080222B (enExample)
AR (1) AR048587A1 (enExample)
AT (1) ATE453387T1 (enExample)
AU (1) AU2005227073B2 (enExample)
CA (1) CA2557806C (enExample)
DE (1) DE602005018613D1 (enExample)
DK (1) DK1727532T3 (enExample)
ES (3) ES2337069T3 (enExample)
IL (2) IL177778A (enExample)
MX (1) MXPA06010928A (enExample)
NO (1) NO337298B1 (enExample)
NZ (1) NZ549664A (enExample)
PL (1) PL1727532T3 (enExample)
PT (1) PT1727532E (enExample)
RU (1) RU2389483C2 (enExample)
TW (1) TWI401078B (enExample)
WO (1) WO2005092310A2 (enExample)
ZA (1) ZA200607291B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054557A2 (en) * 2002-12-18 2004-07-01 Laboratoires Besins International Treatment of mastalgia with 4-hydroxy tamoxifen
JP4684655B2 (ja) * 2002-12-18 2011-05-18 ラボラトワール ブザン アンテルナスィヨナル ４−ヒドロキシタモキシフェンによる乳房密度低下
CA2519980C (en) * 2003-04-01 2012-04-10 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
US7767717B2 (en) 2003-06-09 2010-08-03 Ascend Therapeutics, Inc. Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1799201B1 (en) * 2004-10-14 2008-11-26 Laboratoires Besins International 4-hydroxy tamoxifen gel formulations
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
WO2011046596A2 (en) * 2009-10-13 2011-04-21 Duquesne University Of The Holy Spirit, A Nonprofit Corporation Organized Under The Laws Of The Commonwealth Of Pennsylvania Anti-cancer tamoxifen-melatonin hybrid ligand
CA2878866C (en) * 2011-07-14 2021-02-23 Able Cerebral, Llc A composition, device and method for delayed and sustained release of brain energy molecules
US20230026978A1 (en) * 2021-07-07 2023-01-26 Ohio State Innovation Foundation Photoisomerized compositions of anthocyanins and methods of making and use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
US5475851A (en) * 1986-04-14 1995-12-12 National Instruments Corporation Method and apparatus for improved local and global variable capabilities in a graphical data flow program
US5002938A (en) * 1988-03-21 1991-03-26 Bristol-Myers Squibb Company Antifungal gel formulations
CA2032695A1 (en) 1989-12-20 1991-06-21 Hiroshi Akimoto Condensed heterocyclic compounds, their production and use
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US6160549A (en) * 1994-07-29 2000-12-12 Oracle Corporation Method and apparatus for generating reports using declarative tools
DE4435784C2 (de) * 1994-10-06 1998-10-29 Heraeus Electro Nite Int Elektrisch beheizbarer Starterkat
US5777621A (en) * 1994-12-22 1998-07-07 Apple Computer, Inc. Quality control mechanism for three-dimensional graphics rendering
AU725286B2 (en) * 1996-01-20 2000-10-12 Bradford University Tamoxifen and analogues thereof
ES2156361T5 (es) * 1996-03-29 2012-12-26 Keyvest Gmbh Cosmético o bien composición cosmética para el alisado y la tersura de la piel en el caso de tejido adiposo afectado, en especial en el caso de la "celulitis"
US6083996A (en) * 1997-11-05 2000-07-04 Nexmed Holdings, Inc. Topical compositions for NSAI drug delivery
EP1043986B1 (en) * 1997-12-23 2003-04-16 Hexal Ag Mixture and pharmaceutical composition comprising z-4-hydroxytamoxifen and cyclodextrin
JP2000038335A (ja) * 1998-07-22 2000-02-08 Kanebo Ltd 皮膚化粧料
AU6890800A (en) 1999-08-23 2001-03-19 Eli Lilly And Company A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-D]- pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20030175329A1 (en) * 2001-10-04 2003-09-18 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
PT1317921E (pt) * 2001-12-07 2009-11-06 Besins Mfg Belgium Composição farmacêutica sob a forma de gel ou de solução à base de di-hidrotestosterona, seu processo de preparação e suas utilizações
US6695171B2 (en) * 2002-02-12 2004-02-24 Seaquistperfect Dispensing Foreign, Inc. Pump dispenser
JP4684655B2 (ja) * 2002-12-18 2011-05-18 ラボラトワール ブザン アンテルナスィヨナル ４−ヒドロキシタモキシフェンによる乳房密度低下
WO2004054557A2 (en) * 2002-12-18 2004-07-01 Laboratoires Besins International Treatment of mastalgia with 4-hydroxy tamoxifen
CA2519980C (en) * 2003-04-01 2012-04-10 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
US7767717B2 (en) * 2003-06-09 2010-08-03 Ascend Therapeutics, Inc. Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen
PL1694319T3 (pl) * 2003-12-15 2009-01-30 Besins Healthcare Lu Sarl Zastosowanie 4-hydroksytamoksyfenu do wytwarzania leku do leczenia ginekomastii
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations

Also Published As

Publication number Publication date
NO20064765L (no) 2006-10-20
CA2557806C (en) 2011-08-30
TWI401078B (zh) 2013-07-11
IL177778A0 (en) 2006-12-31
JP5489407B2 (ja) 2014-05-14
AU2005227073B2 (en) 2011-06-23
TW200533334A (en) 2005-10-16
IL215897A0 (en) 2011-12-29
DE602005018613D1 (de) 2010-02-11
AU2005227073A1 (en) 2005-10-06
NZ549664A (en) 2011-01-28
AR048587A1 (es) 2006-05-10
RU2006137282A (ru) 2008-04-27
IL177778A (en) 2011-12-29
EP1579857A1 (en) 2005-09-28
DK1727532T3 (da) 2010-05-03
MXPA06010928A (es) 2006-12-15
NO337298B1 (no) 2016-03-07
EP2269599B1 (en) 2013-02-20
ES2337069T3 (es) 2010-04-20
PT1727532E (pt) 2010-03-30
HK1139332A1 (en) 2010-09-17
ES2402921T3 (es) 2013-05-10
EP1727532A2 (en) 2006-12-06
WO2005092310A3 (en) 2005-12-01
ATE453387T1 (de) 2010-01-15
US20050208139A1 (en) 2005-09-22
EP2147670A1 (en) 2010-01-27
EP2147670B1 (en) 2014-10-01
HK1098674A1 (en) 2007-07-27
CN101080222B (zh) 2013-08-07
ES2517894T3 (es) 2014-11-04
CN101080222A (zh) 2007-11-28
RU2389483C2 (ru) 2010-05-20
WO2005092310A2 (en) 2005-10-06
IL215897A (en) 2014-09-30
EP1727532B1 (en) 2009-12-30
PL1727532T3 (pl) 2010-06-30
JP2007530498A (ja) 2007-11-01
EP2269599A1 (en) 2011-01-05
CA2557806A1 (en) 2005-10-06

Similar Documents

Publication Publication Date Title
PL2335782T3 (pl) Zastosowanie kompozycji zawierającej HFCO-1233zd
EG24416A (en) Amitraz compositions
ITMI20041252A1 (it) Composizioni perfluoroelastomeriche
ZA200705428B (en) Stable prostaglandin-containing compositions
ZA200904425B (en) Nemathical compositions
EP1718714A4 (en) COMPOSITIONS CONTAINING A PLOTTER
IL186673A0 (en) Stable emulsion composition
EP1786437A4 (en) IMPROVED GHB COMPOSITIONS
GB0405406D0 (en) Anti-vaginitis compositions
ZA200704741B (en) Altering properties of fuel compositions
ZA200607291B (en) Chemically stable compositions of 4-hydroxy tamoxifen
ZA200703016B (en) 4-Hydroxy tamoxifen gel formulations
ZA200708527B (en) Use of fuel composition
IL176934A0 (en) Modafinil compositions
GB0504924D0 (en) Perfume compositions
IL186606A0 (en) Compositions and uses of amooranin compounds
GB0412584D0 (en) Composition of matter
GB0505702D0 (en) Perfume compositions
GB0723011D0 (en) Fragrance compositions
ZA200701197B (en) Compositions
GB0410140D0 (en) Compositions
GB0519437D0 (en) Perfume compositions
ZA200702874B (en) Amitraz compositions
GB0512715D0 (en) Fragrance compositions
GB0425445D0 (en) Novel compositions